- Home
- IVA vs RIGL Comparison
IVA vs RIGL Comparison
Compare IVA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- RIGL
- Stock Information
- Founded
- IVA 2011
- RIGL 1996
- Country
- IVA France
- RIGL United States
- Employees
- IVA N/A
- RIGL N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- RIGL Health Care
- Exchange
- IVA Nasdaq
- RIGL Nasdaq
- Market Cap
- IVA 359.6M
- RIGL 335.5M
- IPO Year
- IVA 2020
- RIGL 2000
- Fundamental
- Price
- IVA $3.01
- RIGL $18.93
- Analyst Decision
- IVA Strong Buy
- RIGL Buy
- Analyst Count
- IVA 4
- RIGL 5
- Target Price
- IVA $10.50
- RIGL $36.40
- AVG Volume (30 Days)
- IVA 18.3K
- RIGL 196.7K
- Earning Date
- IVA 03-26-2025
- RIGL 08-05-2025
- Dividend Yield
- IVA N/A
- RIGL N/A
- EPS Growth
- IVA N/A
- RIGL N/A
- EPS
- IVA N/A
- RIGL 2.08
- Revenue
- IVA $14,591,573.00
- RIGL $203,077,000.00
- Revenue This Year
- IVA $15.38
- RIGL $14.41
- Revenue Next Year
- IVA $24.22
- RIGL $15.97
- P/E Ratio
- IVA N/A
- RIGL $9.09
- Revenue Growth
- IVA N/A
- RIGL 70.16
- 52 Week Low
- IVA $1.53
- RIGL $7.48
- 52 Week High
- IVA $4.05
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- IVA 40.84
- RIGL 44.97
- Support Level
- IVA $3.00
- RIGL $18.24
- Resistance Level
- IVA $3.23
- RIGL $19.35
- Average True Range (ATR)
- IVA 0.21
- RIGL 0.90
- MACD
- IVA -0.04
- RIGL -0.14
- Stochastic Oscillator
- IVA 5.08
- RIGL 23.44
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.